Compare TIMB & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TIMB | BMRN |
|---|---|---|
| Founded | 1998 | 1996 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3B | 10.0B |
| IPO Year | 1998 | 1999 |
| Metric | TIMB | BMRN |
|---|---|---|
| Price | $19.33 | $60.41 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 19 |
| Target Price | $22.75 | ★ $89.74 |
| AVG Volume (30 Days) | 370.1K | ★ 3.1M |
| Earning Date | 02-09-2026 | 02-18-2026 |
| Dividend Yield | ★ 9.87% | N/A |
| EPS Growth | 26.01 | ★ 59.53 |
| EPS | 0.31 | ★ 2.68 |
| Revenue | ★ $4,941,546,695.00 | $3,094,001,000.00 |
| Revenue This Year | $8.00 | $13.35 |
| Revenue Next Year | $5.10 | $9.06 |
| P/E Ratio | ★ $12.33 | $22.36 |
| Revenue Growth | 4.96 | ★ 12.39 |
| 52 Week Low | $11.32 | $50.76 |
| 52 Week High | $23.88 | $73.51 |
| Indicator | TIMB | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 24.91 | 64.72 |
| Support Level | $19.84 | $59.36 |
| Resistance Level | $20.28 | $61.79 |
| Average True Range (ATR) | 0.32 | 1.98 |
| MACD | -0.15 | 0.79 |
| Stochastic Oscillator | 2.91 | 72.39 |
TIM, which is 67%-owned by Telecom Italia, is the third largest wireless carrier in Brazil, with 62 million subscribers, equal to about 24% of the market. The firm also owns 49% of I-Systems, an infrastructure partnership that is expanding its network footprint across Brazil. I-Systems can provide broadband service to about 9 million locations, equal to 10%-15% of the country. TIM leases capacity on the venture's network to serve retail broadband customers under the UltraFibra brand. TIM also resells fiber network access from other providers, including Oi's former infrastructure business V.tal.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.